Paddy Ryan

Nutriband Inc.’s patent, ‘Abuse and Misuse deterrent transdermal system’ published by the United States Patent and Trademark Office following recent issuance notice

ORLANDO, Fla., Feb 16, 2022 – Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), has announced that the United States Patent and Trademark Office (USPTO) has published its patent titled “Abuse and Misuse Deterrent Transdermal System” which is related to the Company’s lead technology AVERSA™. US Patent 11,246,840 dated Feb 15, 2022 underpins 4P Therapeutics’ abuse deterrent …

Nutriband Inc.’s patent, ‘Abuse and Misuse deterrent transdermal system’ published by the United States Patent and Trademark Office following recent issuance notice Read More »

Nutriband issued full US patent for its AVERSA™ abuse deterrent transdermal platform by United States Patent and Trademark Office.

ORLANDO, Fla., January 28, 2022 – Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced the receipt of an Issue Notification from the United States Patent and Trademark Office (USPTO) for its United States patent entitled, “Abuse and Misuse Deterrent Transdermal System,”  that protects its AVERSA™ transdermal abuse deterrent technology.   Nutriband’s AVERSA™ abuse deterrent technology can be utilized …

Nutriband issued full US patent for its AVERSA™ abuse deterrent transdermal platform by United States Patent and Trademark Office. Read More »

Nutriband Inc. Expands Product Development Pipeline for Its AVERSA(TM) Platform Abuse Deterrent Technology

ORLANDO, FL / ACCESSWIRE / January 18, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced an expanded product development pipeline for its proprietary AVERSA™ abuse deterrent transdermal technology. The AVERSA abuse deterrent technology platform can be applied to any transdermal patch that has a risk of abuse, misuse or accidental exposure. It is based on incorporating aversive agents …

Nutriband Inc. Expands Product Development Pipeline for Its AVERSA(TM) Platform Abuse Deterrent Technology Read More »

Nutriband Inc. and Kindeva Drug Delivery sign feasibility agreement to develop AVERSA™ Fentanyl, an abuse deterrent fentanyl patch

ORLANDO, Fla., January 10, 2022 – Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced the signing of a feasibility agreement with Kindeva Drug Delivery to develop Nutriband’s lead product, AVERSA™ Fentanyl, based on its proprietary AVERSA™ abuse deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch (fentanyl transdermal system).  The feasibility agreement is focused on adapting Kindeva’s …

Nutriband Inc. and Kindeva Drug Delivery sign feasibility agreement to develop AVERSA™ Fentanyl, an abuse deterrent fentanyl patch Read More »

Nutriband Lead Product Aversa(TM) Fentanyl May Reach Peak Annual Sales of $80-200 Million Based on Market Assessment by Leading Healthcare Consulting Firm

ORLANDO, FL / ACCESSWIRE / January 5, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products has completed the market assessment and commercialization strategy for its lead product candidate, AVERSA™ Fentanyl, an abuse deterrent fentanyl transdermal system. The company engaged leading healthcare consulting company Health Advances to assess the market opportunity …

Nutriband Lead Product Aversa(TM) Fentanyl May Reach Peak Annual Sales of $80-200 Million Based on Market Assessment by Leading Healthcare Consulting Firm Read More »

conference room, table, office

Nutriband Inc. Issued Full Patent from the Korean Intellectual Property Office for Its “Abuse and Misuse Deterrent Transdermal System” Application

ORLANDO, FL / ACCESSWIRE / December 31, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that the Korean Intellectual Property Office (KIPO) has fully issued its patent titled “Abuse and Misuse Deterrent Transdermal System” which is related to the Company’s lead technology AVERSA™. The patent underpins 4p Therapeutics’ abuse deterrent transdermal system, AVERSA, which uses taste aversion …

Nutriband Inc. Issued Full Patent from the Korean Intellectual Property Office for Its “Abuse and Misuse Deterrent Transdermal System” Application Read More »

Nutriband Inc. Announces $1 Million Share Repurchase Authorization

ORLANDO, FL / ACCESSWIRE / December 29, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced a share repurchase program to buy back up to $1,000,000 of its common stock. As of December 29, 2021, the Company had 7,773,962 shares of common stock outstanding. About Nutriband Inc. We are primarily engaged in the development of a portfolio of …

Nutriband Inc. Announces $1 Million Share Repurchase Authorization Read More »

Nutriband Inc. initiates plans to offer Topical lotion contract manufacturing services

ORLANDO, Fla., December 21, 2021 – Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, today announced plans to start offering contract manufacturing services for liquid based topical, transdermal and cosmetic product’s.  This follows the recent certification as a cGMP facility …

Nutriband Inc. initiates plans to offer Topical lotion contract manufacturing services Read More »

Nutriband Inc. Receives cGMP Certification for Manufacturing Subsidiary

ORLANDO, FL / ACCESSWIRE / December 13, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, today announced that its manufacturing subsidiary Active Intelligence, has received cGMP certification following a full cGMP audit. The audit was conducted specifically in relation …

Nutriband Inc. Receives cGMP Certification for Manufacturing Subsidiary Read More »

Nutriband Inc. to Ring NASDAQ Stock Market Opening Bell on December 3, 2021

ORLANDO, FL / ACCESSWIRE / December 3, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, today announced that its Chief Executive Officer Gareth Sheridan and President Serguei Melnik will be joined by members of the Company’s board of directors …

Nutriband Inc. to Ring NASDAQ Stock Market Opening Bell on December 3, 2021 Read More »